Utah State University

DigitalCommons@USU
Undergraduate Honors Capstone Projects

Honors Program

5-1998

Syndrome X: A Review of the Cluster of Abnormalities, Diagnosis,
and Treatment
Kathryn Lundgren Gurney
Utah State University

Follow this and additional works at: https://digitalcommons.usu.edu/honors
Part of the Food Science Commons, and the Nutrition Commons

Recommended Citation
Gurney, Kathryn Lundgren, "Syndrome X: A Review of the Cluster of Abnormalities, Diagnosis, and
Treatment" (1998). Undergraduate Honors Capstone Projects. 894.
https://digitalcommons.usu.edu/honors/894

This Thesis is brought to you for free and open access by
the Honors Program at DigitalCommons@USU. It has
been accepted for inclusion in Undergraduate Honors
Capstone Projects by an authorized administrator of
DigitalCommons@USU. For more information, please
contact digitalcommons@usu.edu.

SYNDROME X: A REVIEW OF THE CLUSTER OF
ABNORMALITIES, DIAGNOSIS, AND TREATMENT

by

Kathryn Lundgren Gurney

Thesis submitted in partial fulfiJlment
of the requirements for the degree
of

DEPARTMENTHONORS

m
Nutrition and Food Sciences

Approved:

Thesis/Project Advisor

Department Honors Advisor

Director of Honors Program

UT AH ST ATE UNIVERSITY
Logan, UT
1998

Abstract
Syndrome Xis a cluster of abnormalities including insulin resistance, hypertension,
dyslipidemia, upper-body obesity, increased levels of plasminogen activator inhibitor 1, decreased
levels of tissue plasminogen activator, and hyperuricemia. The combined effect of these
abnormalities greatly increases risk for Type 2 diabetes and coronary artery disease. Individuals
at risk for Syndrome X are those with any of the abnormalities (not necessarily all) or with a
family history of diabetes, hypertension, or early-onset coronary artery disease. Treatment of
Syndrome X should be early and aggressive, starting with lifestyle changes. Exercise, proper diet,
and weight loss all improve insulin resistance and thereby decrease health risks. Pharmacological
treatment for obesity, dyslipidemia, hypertension, and diabetes may become necessary. Clinicians
should focus on prevention of the disease through advocating an appropriate diet and exercise
plan to maintain or obtain ideal body weight and keep lipids, blood pressure, and glucose at
normal levels.
Introduction
Gerald Reaven introduced the concept of Syndrome X in 1988 (1). Since then, the
concept has been widely accepted and added upon by many clinicians. Other terms to describe
the syndrome are frequently seen in the literature. These include insulin resistance syndrome,
CHAOS (coronary artery disease, hypertension, adult-onset diabetes, and stroke), the deadly
quartet (upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension), or the
GHO syndrome (glucose intolerance, hypertension, and obesity) (2). As eluded to by these terms,
the syndrome consists of a cluster of abnormalities which when present in combination have major
health implications.
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The Cluster of Abnormalities in Syndrome X
The cluster of abnormalities present in Syndrome X includes insulin resistance,
hypertension, dyslipidemia, obesity, increased levels of plasminogen activator inhibitor 1,
decreased levels oftissue plasminogen activator, and hyperuricemia.(l-7).

Insulin resistance is

listed first because it is the core of the syndrome and actually may be the cause for the other
abnormalities seen.
Insulin resistance affects 25% of healthy people (1-6). Both genetic and environmental
factors appear to contribute to the state of insulin resistance (3,4). The disorder appears to be
present in all first degree relatives of diabetic individuals, and it has been shown that children of
Type 2 diabetics become insulin-resistant in their mid-twenties (3). Environmental factors that
contribute are a sedentary lifestyle, smoking, and progressive weight gain (3).
In an insulin resistant state, the body attempts to compensate by secreting more insulin.
This allows euglycemia to be maintained. Though this may seem to be beneficial, the cost is that a
chronic state of hyperinsulinemia results, which can then contribute to other clinical abnormalities
(l,3,5).

Hypertension (HTN), another part of the cluster, appears to be closely associated to
insulin resistance and hyperinsulinemia. Up to 50% of hypertensive subjects are insulin resistant
(5). When insulin therapy is initiated in Type 2 diabetics, blood pressure tends to rise (5). These
points support the hypothesis that insulin resistance and hyperinsulinemia may be causal factors of
HTN.
Hyperinsulinemia contributes to HTN in three ways. First, it causes increased renal
sodium retention (4-6). Second, it causes increased sympathetic nervous system activity (4-6).
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And third, it causes vascular resistance because of insulin's role in stimulating hypertrophy of the
vascular wall (4).
Another abnormality in Syndrome X is dyslipidemia. Again insulin resistance and
compensatory hyperinsulinemia are closely associated with the development of dyslipidemia.
Hypertriglyceridemia and low high-density lipoprotein (HDL) levels are the two main features of
the dyslipidemia (2,4-6). Hyperinsulinemia results in increased lipolysis and subsequent release of
fatty acids. Liver synthesis of very low-density lipoproteins (VLDL) increases, and HDL
production drops (4-6).
Although low-density lipoprotein (LDL) levels rise little if any, there appears to be a
change in the LDL structure that is seen in combination with insulin resistance,
hypertriglyceridemia, and low HDL levels (2,5). These LDL particles are smaller and denser and
have been classified as pattern B LDL, whereas pattern A LDL is the larger, normal pa11iclesize
typically seen. Pattern B LDL increases the risk of coronary artery disease, and Reaven ( 1) states
that the risk of myocardial infarction (Ml) is three times higher in subjects with these smaller,
denser LDL ( 1).
Hyperinsulinemia also promotes atherogenesis. Again, this is due to the role of insulin in
stimulating smooth muscle cell proliferation which promotes lipid deposition (4,6).
Most clinicians agree that obesity, particularly upper-body obesity, is part of Syndrome X.
However, there has been some controversy over the issue. Those that include obesity argue that
HTN, hypertriglyceridemia, and diabetes are more common in obese subjects, and obese subjects
are more insulin resistant( 4,5). It has been shown that individuals 3 5-40% above their ideal body
weight show a 30-40% decrease in insulin sensitivity (4). Thus there seems to be enough of an
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association to include it in the syndrome. Reaven (5) disagrees and states that obesity is not an
essential component of the syndrome because the other abnormalities already discussed can and
do appear independently of obesity. He does, however agree that obesity can exacerbate the
other abnormalities (5).
The remaining abnormalities have been recognized more recently as part of Syndrome X.
Increased levels of plasminogen activator inhibitor 1 (P AI-1) appear to be associated with
hyperinsulinemia, hypertriglyceridemia, and HTN (2,5). P AI-1 inhibits fibrinolysis and thus
increases the risk of arterial occlusion and Ml (1,4)
Tissue plasminogen activator (tP A) levels are inversely associated with insulin
concentration (2). Because tPA is the principle mediator of clot lysis, decreased levels as seen in
the syndrome also contribute to the risk of occlusion (2).
Hyperuricernia also seems to be part of the cluster of abnormalities because it appears to
be highly correlated with hypertriglyceridemia, low HDL, HTN, and insulin resistance (l,2,4,5).
To summarize the cluster of abnormalities seen in Syndrome X, insulin resistance seems to
be at the core with both genetics and environment contributing to its development

From then on,

a cascade of abnormalities may result Chronic hyperinsulinemia may lead to frank diabetes as the
P-cells are unable to compensate and begin to fail (1,3,5). Hyperglycemia then becomes
inevitable. Diabetes in combination with the other abnormalities HTN, dyslipidernia, high P Al-1,
and low tP A greatly increase an individual's risk of coronary artery disease.

Diagnosis of Syndrome X
Although measuring glucose, blood pressure, and serum lipids is quite simple,
measurement of insulin resistance, the core of Syndrome X, is much more difficult (4,6). To add
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to the difficulty, there really is no quantitative definition of insulin resistance (6) One possibl~
clinical symptom of insulin resistance has been identified. Obesity-related acanthosis nigricans
appears to be associated with insulin resistance and presents as a hyperpigmented, hypertrophic,
velvety dermatosis on the axillae, nape and sides of the neck, groin, antecubital and popliteal
surfaces, and umbilical area (3,4). Additionally, it has been suggested that ifHTN,
hypertriglyceridemia, and low HDL levels co-exist, insulin resistance is probable (3).
Aside from identifying insulin resistance, Syndrome X may be suspected in an individual
who presents with Type 2 diabetes, hypertension, dyslipidemia, and/or central obesity (not
necessarily all in combination) (4). Further, it has been suggested that the syndrome may be
suspected in any individual with a family history of diabetes, hypertension, or early-onset coronary
artery disease (3).

Treatment of Syndrome X
Individuals diagnosed or at risk of Syndrome X should be treated early and aggressively
(3). Treatment may consist of both nonpharmacological and pharmacological intervention, the
former being "the cornerstone of treatment"(3). Weight loss, even limited weight loss, can
improve insulin sensitivity (3,5,7). Exercise improves insulin sensitivity regardless if weight loss
occurs (7), and also decreases lipid levels (4). lt has been estimated that the risk of Type 2
diabetes is 36% lower in men exercising at least once per week (4). Recent national guidelines for
exercise have been proposed for Americans to reduce health risks (8). It is recommended that
1000 kcalories in physical activity be expended per week, which amounts to approximately 30-40
minutes, 5-7 days per week. Quantity and frequency of exercise is being stressed rather than
intensity. However, for the subgroup of the population with Syndrome X, moderate intensity
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exercise (such as walking, jogging, or biking) has been suggested. Exercise also appears to be a!?
beneficial in short non-continuous increments. For example, three 10 minute sessions is as effect
as one 30 minute exercise session (8).
Diet therapy can aid in weight loss and reduction of health risk, yet the perfect diet
prescription tends to be a controversial topic. The typical recommendation of a high
carbohydrate, low fat diet may not apply to this population (7,9). Reaven suggests "such diets
accentuate the metabolic abnormalities that constitute Syndrome X," and should be avoided (9).
His argument makes sense in that higher carbohydrate intake would result in a rise in insulin
secretion which may further aggravate the hyperinsulinemic state There is evidence that a high
carbohydrate (high-CHO) diet may increase triglyceride and VLDL levels, lower HDL, and
worsen glycemic control ( 10,11). A high mono-unsaturated (HM) fat diet with moderate
carbohydrate intake has been proposed to prevent these effects ( 10, 11, 13).
Campbell et al (10) conducted a study with 10 Type 2 diabetic men. Each man went on a
2-week high-CHO diet (55% CHO, 8% mono) followed by a 2-week HM diet (22% mono, 40%
CHO). Their results showed fasting plasma triglycerides and mean prandial glucose were
significantly lower with the HM diet in comparison to the high-CHO diet. Fasting total
cholesterol and HDL values showed no significant difference. Participants in the study also rated
both diets similar in acceptance, cost and ease of preparation. Campbell et al concluded that a
HM diet could be an alternative to a high-CHO diet for Type 2 diabetics.
Garg et al (11) put 10 Type 2 diabetic men on a 4-week high-CHO diet (65% CHO)
followed by a 4-week HM diet (31 % mono, 38% CHO). Their results showed the high-CHO diet
"caused a significant but modest accentuation of hyperglycemia" as well as raising triglyceride and
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VLDL levels. They concluded that high-CHO diets may worsen glycemic control in Typ~ 2
diabetes and may not be desirable in these patients.
Another study conducted by Bonanome et al (12) put 19 Type 2 diabetic subjects on a 2month high-CHO diet (60% CHO, 10% mono) followed by a 2-month HM diet (25% mono, 45%
CHO) Their results showed no significant changes in total cholesterol, triglyceride, LDL, HDL,
or fasting glucose concentrations. They concluded that a HM diet could be used as an alternative
to a high-CHO diet in Type 2 diabetes and may offer more food choices resulting in better
compliance.
It should be noted that each of these studies used diabetic subjects, and individuals with
Syndrome X are not necessarily diabetic (though they are at great risk of developing diabetes).
Insulin resistance and compensatory hyperinsulinemia are common among both subjects, and in
fact hyperinsulinemia is more profound in insulin resistant subjects not yet diagnosed with
diabetes (P-cell failure in diabetes results in less insulin secretion) (5). Therefore, a HM diet may
be even more applicable for non-diabetic individuals who are diagnosed with Syndrome X to
control the rise in insulin and lipids.
The American Diabetes Association (ADA) suggests a HM diet include less than 10% of
kcalories from saturated fat, less than 10% of kcalories from poly-unsaturated fat with up to 20%
of kcalories from mono-unsaturated fats, and "moderate intake of carbohydrate ( 13). "
Pharmacological therapy may become necessary if improvements are not seen with
lifestyle changes. Anti-obesity medications may be indicated, particulary for patients who are
non-compliant with lifestyle changes (3). Dyslipidemia may be treated pharmacologically using
gemfibrozil (lopid) or clofibrate, both of which work to decrease triglycerides and VLDL and
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increase HDL (3,4). Additionally, gemfibrozil may improve clot lysis ability, thereby decreasing
the risk for arterial occlusion (3). Hypertension should be treated with an angiotensin-convertingenzyme inhibitor such as captopril or lisinopril (3,4). These medications increase insulin-mediated
glucose uptake (3,4). Diuretics and P-blockers are not recommended inasmuch as they aggravate
glucose tolerance and increase serum lipids (4, 7).
lf diabetes develops due to P-cell failure to compensate with adequate insulin,
pharmacological treatment may become necessary (if control is not achieved with diet and
exercise) (14). Oral medications are typically tried first. Sulfonylureas (i.e. diabeta) enhance
insulin secretion and decrease hepatic glucose output. Metformin (glucophage) decreases hepatic
glucose production and increase glucose uptake, and is used alone or in combination with a
sulfonylurea. The most recent approved drug troglitazone (rezulin) is the first anti-diabetic drug
that actually improves the state of insulin resistance. It is to be used in combination with a
sulfonylurea or insulin. Cases of hepatocellular injury have been reported with the use of
troglitazone, so frequent monitoring ofliver function is essential (14, 15).
Without improvement in glucose control, insulin may then become necessary. There is
strong evidence from the Diabetes Control and Complications Trial (DCCT) that intensive
diabetes management can decrease diabetes-associated complications ( 14). However, there is
some question as to whether this applies as strongly to Type 2 diabetics. Because of their insulin
resistant state, they require large doses of insulin to achieve euglycemia - doses as high as 100
units per day (14). Weight gain is also problematic with insulin therapy (14). Due to
complications already discussed associated with hyperinsulinemia, it becomes necessary to
provide the least amount of insulin therapy possible to achieve euglycemia (14).
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Yki-Jarvinen et al (16) conducted a study on 153 Type 2 diabetics with poor control on
oral medications to discover the best treatment modality to achieve euglycemia. The four
treatment groups consisted of 1) oral medication plus NPH insulin in the morning, 2) oral
medication plus evening NPH, 3) a combination ofNPH and regular insulin twice a day (no
orals), and 4) regular insulin three times a day plus evening NPH. Equivalent control was
achieved in all treatment groups, however twice as much insulin was required in the treatment
groups without oral medications. The least amount of weight gain was achieved in the oral
medication plus evening NPH group. Based on these findings, a combination of oral medications
and insulin is optimal. Diet and exercise would also contribute significantly to obtaining glycemic
control without further adding to hyperinsulinemia.

Conclusion
Syndrome X is a deadly combination of abnormalities which greatly increases an
individual's risk of developing Type 2 diabetes and coronary artery disease. Treatment should be
early and aggressive to achieve normal lipid, blood pressure, and glucose levels. Because 1/4 of
the population is ultimately at risk for this deadly syndrome due to insulin resistance, clinicians
should focus on prevention of the disease through advocating an appropriate diet and exercise
plan to maintain or obtain ideal body weight and keep lipids, blood pressure, and glucose at
normal levels.
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